Tumor neoantigen-specific T cell activation (null)

Tumor neoantigen-specific T cell activation refers to the immunologic activation of T cells in response to tumor-derived neoantigens—proteins bearing unique mutations not found in normal tissues, arising from somatic DNA mutations in cancer cells[3][7][8]. These neoantigens are processed and presented on MHC molecules and recognized by T cell receptors (TCR) on cytotoxic (CD8+) and helper (CD4+) T cells, leading to targeted immune responses against cancer cells. This process underpins much of the efficacy seen with immune checkpoint inhibitors, cancer vaccines, and adoptive T cell therapies. Unlike shared tumor antigens, neoantigens are tumor-specific and less likely to induce autoimmunity, making them highly desirable for immunotherapeutic targeting. However, challenges such as immune editing, T cell exhaustion, and heterogeneity of neoantigen expression complicate robust and durable clinical responses[3][5][7][8]. In summary: While tumor neoantigen-specific T cell activation is central to modern cancer immunotherapy, it is not a single molecular target, but a therapeutic process or response. It should not be catalogued as a canonical molecule, receptor, or protein target.

Other names

neoantigen-specific T cell responsetumor-specific T cell activationneoepitope-driven T cell response

Drugs modulate this process by: Enhancing T cell recognition/activation via neoantigen presentation (vaccines, adoptive T cell transfer); Inhibiting immunosuppressive pathways (immune checkpoint blockade); Inducing immunogenic cell death, increasing neoantigen release (chemotherapy, radiation, oncolytic viruses).